Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK Pathway Mutations
This is a phase 2 study testing how well the study medicines vismodegib (a Hedgehog pathway inhibitor), GSK2256098 (a selective focal adhesion kinase (FAK) inhibitor), and capivasertib (an ATK kinase inhibitor) work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). All patients will have genetic testing done before entering the study to check for changes in their tumor genes (mutations). One treatment group of this trial (the capivasertib arm) remains open to enrollment for patients at NYU. The study team will find out if patients receiving the study medicine live longer overall and how long it takes for their cancer to spread and get worse. Blood samples will be collected from all patients to see how their bodies are handling the study medicine. Special scans will be done for all patients to see how the study medicines are changing their cancer. All patients will be closely monitored for side effects and safety concerns and will be followed up for up to 5 years after registration in the study.
PHASE II/III SECOND-LINE NABPLAGEM VS. NAB-PACLITAXEL/GEMCITABINE IN BRCA1/2 OR PALB2 MUTANT METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PLATINUM)
This is a phase II/III study testing whether the study medicines, Nab-paclitaxel plus cisplatin and gemcitabine, work better than the standard chemotherapy medicine Nab-paclitaxel plus gemcitabine for patients with BRCA1/2 or PALB2 mutant pancreatic cancer who have received FOLFIRINOX treatment before. The patients will be part of one of the two treatment groups. Group A will receive the study medicines called Nab-paclitaxel plus cisplatin and gemcitabine, and Group B will receive Nab-paclitaxel plus gemcitabine. The study team will take blood samples from all patients to learn more about the treatment and monitor how the patients are doing. Patients will have special scans taken to see how the study medicine changes the tumor size. Patients will be closely watched for side effects and discomfort and followed for up to 2 years after their last treatment.
PHASE II: ADAPTIVE TREATMENT DE-ESCALATION IN FAVORABLE RISK HPV-POSITIVE OROPHARYNGEAL CARCINOMA
This will be a phase II single-arm clinical trial. The primary objective of this study is to evaluate progression-free survival at 2 years.The secondary objectives will include 2-year locoregional control and overall survival, quality of life, and late toxicity. Quality of life outcomes can be assessed with a validated, self-reported questionnaire. Late toxicity can be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events. Additionally, the prognostic value of positive HPV in salivary rinse as well as plasma at mid and post- treatment time points will be evaluated with a baseline evaluation pre-treatment. Radiomic analysis of pre-treatment imaging will be correlated with outcomes.
Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) For Intact Brain Metastases
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Phenotypic and genotypic study of Keratoconus
Keratoconus is a disease in which the cornea is abnormally steep and thin. It affects approximately 1 in 2000 individuals and usually begins in the second decade of life. Keratoconus is a progressive disorder which results in loss of vision that cannot be alleviated by contact lenses or glasses alone, and is a leading indication for corneal transplantation in developed countries (Udar et al., IOVS 47: 3445-3351, 2006). Keratoconus has a strong genetic component, and while several genes are suspected clear causative genes and underlying pathogenic processes have not been identified yet. We will enroll isolated keratoconus and familial cases and unaffected members of the families when available. The goal of our research is to identify genes that harbor mutations that contribute to keratoconus and underlying biochemical processes that are altered as a result and contribute to keratoconus pathogenesis. The subject population consists of individuals diagnosed with keratoconus and unaffected relatives in families. Individuals/families are ascertained through support groups, web-based listings of research studies and genetic testing services, and a keratoconus research website that Dr. Chakravarti and other team members maintain. The identities of the study participants will be known only to Dr. Chakravarti, the study coordinator, physicians in the team and the post-doctoral fellow(s) working directly on the project.DNA, lymphocytes, and lymphoblastoid cell lines may be prepared from the blood samples for future use. Molecular analysis using markers and sequencing, and statistical analysis of these data, will be used to identify regions of human chromosomes where putative keratoconus disease genes reside. Analyses of DNA sequences of all coding region of genes from keratoconus subjects compared to published control subjects DNA will be performed to identify disease specific variants. Additionally to understand disease pathogenesis, subsets of patients may be asked to provide tear samples or impression cytology of their conjunctiva (a thin tissue paper is placed under the eyelid area and lifted off which brings small number of patient cells that can be visualized by histology). Study subjects will not directly benefit from participation; the purpose of the study is to better understand the etiology of keratoconus, leading to improved detection, treatment, and management. Results will not be disclosed to participants nor their health care providers, unless medically relevant.
PHINDER: Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection
The PHINDER study is a research study that will collect data to better understand screening for pulmonary hypertension (PH). The goal is to use the data collected to potentially improve PH screening in people who have interstitial lung disease (ILD). Participation in the PHINDER study will help researchers learn more about early detection of PH. The PHINDER study includes procedures that your doctor routinely performs in the care of ILD patients. There is no experimental treatment included in this study and all study-related procedures will be provided at no cost.
Photodynamic Therapy for Macular Degeneration | NYU Langone Health
NYU Langone doctors can perform photodynamic therapy in conjunction with injections to manage wet macular degeneration.
Photopheresis for Cutaneous T-Cell Lymphoma | NYU Langone Health
NYU Langone doctors may use photopheresis to treat cutaneous T-cell lymphoma found in the blood.
Phototherapy & Laser Treatment for Vitiligo | NYU Langone Health
NYU Langone dermatologists use phototherapy and laser treatments to minimize the appearance of white patches caused by vitiligo.
Phototherapy for Eczema & Dermatitis | NYU Langone Health
NYU Langone doctors offer phototherapy to relieve symptoms of eczema and dermatitis.